Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s stock price was down 25.9% on Thursday . The company traded as low as $0.30 and last traded at $0.30. Approximately 753,013 shares changed hands during trading, an increase of 8% from the average daily volume of 697,326 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Stock Performance
The firm’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.72.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
See Also
- Five stocks we like better than Altamira Therapeutics
- Stock Market Upgrades: What Are They?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Invest in Biotech Stocks
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
